Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
11:41am, Wednesday, 26'th Feb 2025
Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash posi
Why Madrigal Pharmaceuticals Stock Is Soaring Today
11:27am, Wednesday, 26'th Feb 2025
Shares of Madrigal Pharmaceuticals (MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday.
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript
11:05am, Wednesday, 26'th Feb 2025
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript
Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates
09:31am, Wednesday, 26'th Feb 2025
Madrigal (MDGL) came out with a quarterly loss of $2.71 per share versus the Zacks Consensus Estimate of a loss of $4.12. This compares to loss of $5.68 per share a year ago.
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
08:00am, Friday, 21'st Feb 2025
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
08:00am, Wednesday, 12'th Feb 2025
CONSHOHOCKEN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wedn
MoneyShow's Best Investment Ideas For 2025: Part 7
11:50am, Wednesday, 29'th Jan 2025
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur
Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH
09:30am, Sunday, 19'th Jan 2025
Madrigal Pharma's REZDIFFRA achieved $100-$103M in Q4 sales, marking 61% growth, with market penetration of only 4% relative to TAM, indicating blockbuster potential. Potential competition from GLP-1
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
08:28am, Friday, 17'th Jan 2025
An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (MDGL -0.59%) stock out of the doldrums over the past few trad
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
10:46am, Wednesday, 15'th Jan 2025
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
Why Madrigal Pharmaceuticals Stock Is Sinking Today
11:20am, Monday, 13'th Jan 2025
Shares of Madrigal Pharmaceuticals (MDGL -13.81%) were sinking 13.3% lower as of 11:11 a.m. ET on Monday.
CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associ
Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
06:22am, Thursday, 09'th Jan 2025
Rezdiffra's strong launch has been confirmed by robust sales in the first two quarters, even though it may have only been used in 2% of its current target patient population. Competitors with MASH the
